Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, Predictive Bio Partner on Bladder Cancer Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced it has licensed certain DNA methylation biomarkers to Predictive Biosciences for the development of bladder cancer diagnostics.

Under the deal, Predictive has exclusive rights in the United States to use the biomarkers to develop the tests and will pay MDxHealth upfront and milestone payments as well as royalties on net sales.

MDxHealth, which is undergoing a restructuring, retains the worldwide exclusive rights to the markers for tissue-based bladder cancer tests. No further terms were disclosed.

"We believe that collaborating with partners who focus on one disease area is a better way to leverage our biomarkers for cancer screening as these dedicated companies stand a greater chance of bringing these products successfully to market," MDxHealth CEO Jan Groen said in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.